바이젠셀
5,340KRWMarket close of 10/21 (Wed)
Down -0.19%-10KRWMarket close of 10/21 (Wed)
- Open
- 5,300
- High
- 5,600
- Low
- 5,270
- Day range
- Day range low 5,270 high 5,600, open 5,300, close 5,340, previous close 5,350
- Volume
- 7×10K shares
- 355.72 million KRW 0.75× the 20-session average
Market close of 10/21 (Wed)
Where it sits in the 1-year range
18%1-year close range 3,090 to 15,800 won, 18% up from the low
18% of the way up from the lowest close in 1 year (252 sessions) · -66.2% from the high
Something to check
1 to check: operating loss
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsto check-13.6B KRWOperating income over the last four quarters -13.6B KRW (loss)
- Recent filingsnot verifiedOutside filing data coverage, so not verified
- Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
The other 3 are within the usual range
- Daily move-0.19%usual range
- Trading value0.7×usual range
- Data date10/21 (Wed)Market close
See the full check report
Quarterly results · Q1 2025
- Revenue0 KRW
- vs. year ago
- —
- vs. prior quarter
- -100.0%
- Operating income-2.7B KRW
- vs. year ago
- Still a loss
- vs. prior quarter
- Still a loss
Quarterly operating income trend
As of the latest official close · 2026-10-21Valuation filing date · 2025-05-15Same sector · 바이오 R&D
Up +3.03%· 33 of 64 stocks up, preferred shares excluded · trading value 215.2B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -5.5% | Up +3.90% | 60.7B KRW |
| 올릭스 | Close over the last 20 sessions -6.4% | Up +9.53% | 26.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -6.0% | Up +6.65% | 22.0B KRW |
| 리가켐바이오 | Close over the last 20 sessions -14.3% | Up +2.00% | 12.9B KRW |
| 프로티나 | Close over the last 20 sessions +35.7% | Up +7.23% | 11.0B KRW |
Schedule
- Next data 10/23 (Fri) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.